Drug intelligence / Profile preview

GIC-302

Development stage: Preclinical
Lead developer: GI Cell
Modality: Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GIC-302 is a T-lymphocyte cell therapy under development by GI CELL Co. Ltd. for the treatment of inflammatory bowel diseases, which are categorized under digestive system disorders. The drug is currently in the preclinical stage of development and has not yet entered clinical trials or received regulatory approval. Specific details regarding its mechanism of action, molecular targets, or additional pharmacological properties have not been disclosed in public sources as of January 2025[1][2].

Beyond the preview

Go deeper on GIC-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GIC-302.

Explore the full profile